Skip to main content

Abdominal Abscess

4
Pipeline Programs
3
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

Pfizer
TYGACILApproved
tigecycline
Pfizer
Tetracycline-class Antibacterial [EPC]intravenous2005
85K Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
1
tigecyclinePhase 4Small Molecule1 trial
tigecyclinePhase 3Small Molecule1 trial
Active Trials
NCT00136201Completed200Est. Dec 2006
NCT00488306Completed50Est. Aug 2007
Argon Medical Devices
1 program
1
Catheter SclerotherapyPhase 1/21 trial
Active Trials
NCT06906029Not Yet Recruiting60Est. Jul 2028
Genentech
GenentechCA - Oceanside
1 program
AlteplasePHASE_21 trial
Active Trials
NCT00284739Completed20Est. Oct 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Pfizertigecycline
Pfizertigecycline
GenentechAlteplase
Argon Medical DevicesCatheter Sclerotherapy

Clinical Trials (4)

Total enrollment: 330 patients across 4 trials

NCT00488306Pfizertigecycline

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Start: Aug 2006Est. completion: Aug 200750 patients
Phase 4Completed
NCT00136201Pfizertigecycline

Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections

Start: Nov 2005Est. completion: Dec 2006200 patients
Phase 3Completed
NCT00284739GenentechAlteplase

Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses

Start: Feb 2006Est. completion: Oct 200720 patients
Phase 2Completed
NCT06906029Argon Medical DevicesCatheter Sclerotherapy

Abdominal aBscess Catheter Sclerotherapy (ABCS)

Start: Jul 2026Est. completion: Jul 202860 patients
Phase 1/2Not Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.